HC Wainwright Reiterates “Buy” Rating for Vir Biotechnology (NASDAQ:VIR)

HC Wainwright restated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a report published on Monday morning, Benzinga reports. They currently have a $110.00 price objective on the stock. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2024 earnings at ($0.66) EPS, FY2024 earnings at ($3.70) EPS, Q1 2025 earnings at ($0.68) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.08) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.17) EPS and FY2028 earnings at ($1.45) EPS.

Other analysts have also issued research reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Friday, November 1st. Barclays cut their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $10.17 on Monday. Vir Biotechnology has a 52-week low of $7.12 and a 52-week high of $13.09. The company has a fifty day moving average of $7.80 and a 200-day moving average of $8.90. The company has a market capitalization of $1.39 billion, a P/E ratio of -2.59 and a beta of 0.46.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. During the same period last year, the firm earned ($1.22) EPS. The company’s revenue for the quarter was down 9.8% on a year-over-year basis. As a group, analysts forecast that Vir Biotechnology will post -3.48 EPS for the current fiscal year.

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $7.80, for a total value of $95,082.00. Following the sale, the director now owns 11,616 shares of the company’s stock, valued at $90,604.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 15,940 shares of company stock valued at $127,410 over the last three months. 15.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vir Biotechnology

A number of large investors have recently made changes to their positions in the business. Innealta Capital LLC purchased a new stake in shares of Vir Biotechnology in the 2nd quarter worth about $32,000. Blue Trust Inc. raised its stake in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after buying an additional 2,351 shares in the last quarter. nVerses Capital LLC purchased a new stake in Vir Biotechnology in the third quarter worth about $56,000. Magnetar Financial LLC bought a new stake in Vir Biotechnology during the 2nd quarter valued at approximately $95,000. Finally, Headlands Technologies LLC purchased a new position in shares of Vir Biotechnology during the 1st quarter worth approximately $119,000. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).